Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study
- PMID: 22767635
- DOI: 10.1210/jc.2012-1690
Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study
Abstract
Context: Polycystic ovary syndrome (PCOS) is associated with insulin resistance, hyperandrogenism, and dyslipidemia, but the effects of these disturbances on long-term health are not fully understood.
Aim: Our aim was to determine the relative risk of type 2 diabetes, cancer, large-vessel disease (LVD), and all-cause mortality for women diagnosed with PCOS.
Design: Data were extracted from the General Practice Research Database, a longitudinal, anonymized research database derived from nearly 600 primary-care practices in the United Kingdom. Patients with a diagnosis of PCOS between 1990 and 2010 were selected. Patients were matched to two sets of controls. The first set was matched according to primary-care practice and age, and the second was also matched on body mass index. Primary outcome was first incident record of diabetes. Crude rates for diabetes were presented, and time to diabetes was analyzed using Cox proportional hazard models. Secondary outcomes (cancer, LVD, and mortality) were also modeled.
Results: Of 53,303 identified with a diagnosis of PCOS, 21,740 (40.8%) met the eligibility criteria. Median follow-up was 4.7 yr (interquartile range = 2.0-8.6 yr) in those with PCOS and 5.8 yr (2.7-9.6) in the reference group. Crude rates of diabetes were 5.7 and 1.7 per 1000 patient-years for cases and controls, respectively. The corresponding adjusted hazard ratio was 3.015 (95% confidence interval = 2.733-3.327). Of cases matched by body mass index, crude rates of diabetes were 4.7 and 2.4 per 1000 patient-years, respectively. The corresponding adjusted hazard ratio was 1.752 (1.514-2.028). No significant difference in BMI-adjusted risk was evident for cancer, LVD, or all-cause mortality.
Conclusions: During this follow-up period, women with PCOS were not at increased risk of LVD, cancer, or death, but they had increased risk of type 2 diabetes.
Similar articles
-
Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study.J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3369-e3380. doi: 10.1210/clinem/dgab392. J Clin Endocrinol Metab. 2021. PMID: 34061968 Free PMC article.
-
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.J Clin Endocrinol Metab. 2010 May;95(5):2038-49. doi: 10.1210/jc.2009-2724. Epub 2010 Apr 7. J Clin Endocrinol Metab. 2010. PMID: 20375205 Review.
-
Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63. doi: 10.1210/jc.2005-2430. Epub 2006 Jan 24. J Clin Endocrinol Metab. 2006. PMID: 16434451
-
Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.Hum Reprod. 2014 Sep;29(9):2041-9. doi: 10.1093/humrep/deu180. Epub 2014 Jul 17. Hum Reprod. 2014. PMID: 25035436
-
Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence.Minerva Ginecol. 2004 Feb;56(1):27-39. Minerva Ginecol. 2004. PMID: 14973408 Review.
Cited by
-
Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.Curr Cardiol Rep. 2024 Jun;26(6):483-495. doi: 10.1007/s11886-024-02050-5. Epub 2024 Apr 3. Curr Cardiol Rep. 2024. PMID: 38568339 Review.
-
Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort.CJC Open. 2023 Dec 16;6(2Part B):314-326. doi: 10.1016/j.cjco.2023.12.010. eCollection 2024 Feb. CJC Open. 2023. PMID: 38487056 Free PMC article.
-
The Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date.Medicina (Kaunas). 2024 Jan 30;60(2):244. doi: 10.3390/medicina60020244. Medicina (Kaunas). 2024. PMID: 38399531 Free PMC article. Review.
-
Reproductive risk factors across the female lifecourse and later metabolic health.Cell Metab. 2024 Feb 6;36(2):240-262. doi: 10.1016/j.cmet.2024.01.002. Epub 2024 Jan 26. Cell Metab. 2024. PMID: 38280383 Review.
-
Up-regulation of miR-133a-3p promotes ovary insulin resistance on granulosa cells of obese PCOS patients via inhibiting PI3K/AKT signaling.BMC Womens Health. 2022 Oct 8;22(1):412. doi: 10.1186/s12905-022-01994-6. BMC Womens Health. 2022. PMID: 36209087 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous